Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Receivables - Net (2018 - 2025)

Historic Receivables - Net for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $80.7 million.

  • TransMedics' Receivables - Net fell 1045.85% to $80.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.7 million, marking a year-over-year decrease of 1045.85%. This contributed to the annual value of $97.7 million for FY2024, which is 5370.89% up from last year.
  • As of Q3 2025, TransMedics' Receivables - Net stood at $80.7 million, which was down 1045.85% from $104.9 million recorded in Q2 2025.
  • Over the past 5 years, TransMedics' Receivables - Net peaked at $142.0 million during Q1 2025, and registered a low of $4.1 million during Q3 2021.
  • Over the past 5 years, TransMedics' median Receivables - Net value was $47.5 million (recorded in 2023), while the average stood at $51.9 million.
  • In the last 5 years, TransMedics' Receivables - Net tumbled by 3242.14% in 2021 and then surged by 43096.39% in 2022.
  • TransMedics' Receivables - Net (Quarter) stood at $5.9 million in 2021, then skyrocketed by 365.3% to $27.6 million in 2022, then skyrocketed by 130.26% to $63.6 million in 2023, then surged by 53.71% to $97.7 million in 2024, then decreased by 17.42% to $80.7 million in 2025.
  • Its Receivables - Net was $80.7 million in Q3 2025, compared to $104.9 million in Q2 2025 and $142.0 million in Q1 2025.